Patients with mild pulmonary fibrosis generally do not have an impact on their life expectancy if they are treated aggressively, but without treatment the disease can easily progress further and survival is only 2-5 years in cases of severe pulmonary impairment. Pulmonary fibrosis is an interstitial lung disease in which the normal alveolar tissue is damaged and repaired to form structural abnormalities. It can lead to progressive loss of lung function, and most of the causes are unknown, and there is no effective treatment available. Patients with mild pulmonary fibrosis can be controlled to further deteriorate without affecting their life expectancy and quality of life if active intervention is performed, but patients with poor control or even without treatment will have rapid aggravation and deteriorating respiratory function, with most patients surviving for only 2-5 years. The treatment measures for patients with pulmonary fibrosis are mainly symptomatic, including anti-inflammatory, cough suppressant and wheezing, etc. Drugs to prevent the progression of pulmonary fibrosis can be taken, and attention should be paid to avoiding exposure to harmful substances and preventing infection.